Linked Life Data

18157705

Source:http://linkedlifedata.com/resource/pubmed/id/18157705

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-2-15
pubmed:abstractText
To evaluate the effect of moderate liver impairment on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093, ESL), a novel voltage-gated sodium channel blocker currently in clinical development.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0031-6970
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
267-73
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment.
pubmed:affiliation
Department of Research and Development, BIAL (Portela & Ca SA), A Av. da Siderurgia Nacional, 4745-457, S Mamede do Coronado, Portugal.
pubmed:publicationType
Journal Article, Controlled Clinical Trial